• Value Research Rating market-capitalisation-info
    Not Applicable
  • Market Capitalisation market-capitalisation-info $2,621 Mln
  • Price to Earnings Ratio price-to-earning --
  • 12 Month Earnings monthly-earning $-191 Mln

Rocket Pharmaceuticals Inc. (RCKT) Share Price

$28.71

As on 04-Mar-2024 16:00 EST

up-down-arrow $-1.82-5.96%

  • Prev Close info

    $30.53

  • Day's Openinfo

    $30.88

  • Today's Highinfo

    $30.94

  • Today's Lowinfo

    $28.60

  • Today's Volumeinfo

    728,838

  • 52 Week rangeinfo

    $14.89 - 32.45

Please wait...

Rocket Pharmaceuticals Inc. (RCKT) Stock Performance

YTD
1 Month
3 Months
1 Year
3 Years
5 Years
10 Years
Rocket Pharmaceuticals (RCKT)
-4.20 0.56 22.59 37.83 -18.45 10.46 --
S&P BSE Sensex*
1.99 2.21 6.99 23.19 13.16 15.36 13.26
S&P Small-Cap 600#
-5.82 -5.34 -13.73 -6.30 5.30 2.98 5.53
As on 04-Mar-2024  |  *As on 05-Mar-2024  |  #As on 26-Oct-2023
2023
2022
2021
2020
2019
2018
2017
Rocket Pharmaceuticals (RCKT)
53.14 -10.35 -60.19 140.95 53.58 41.68 -57.21
S&P Small-Cap 600
13.89 -17.42 25.27 9.57 20.86 -9.70 11.73
S&P BSE Sensex
18.74 4.44 21.99 15.75 14.38 5.87 27.91

Valuation Score

Stock
Peer Median
Please wait...

Growth & Efficiency

Stock
Peer Median
Please wait...

Solvency

Is there a threat to this company's solvency in the future?

Financial Manipulation

Can creative accounting be detected through the financial numbers?

Rocket Pharmaceuticals Inc. (RCKT) Peer Comparison

search
search
search
search
    Please wait...

    Valuation Chart of Rocket Pharmaceuticals Inc. (RCKT)

      Please wait...
        Please wait...

        Financials

        Please wait...
        Please wait...
        Please wait...

        Shareholding Pattern

        Other details of Rocket Pharmaceuticals Inc. (RCKT)

        CEO & Director

        Dr. Gaurav D. Shah M.D.

        President & COO

        Ms. Kinnari Patel M.B.A., Pharm.D.

        Headquarters

        Cranbury, NJ

        FAQs for Rocket Pharmaceuticals Inc. (RCKT)

        The total asset value of Rocket Pharmaceuticals Inc. (RCKT) stood at $ 632 Mln as on 30-Sep-23

        The share price of Rocket Pharmaceuticals Inc. (RCKT) is $28.71 (NASDAQ) as of 04-Mar-2024 16:00 EST. Rocket Pharmaceuticals Inc. (RCKT) has given a return of -18.45% in the last 3 years.

        Rocket Pharmaceuticals Inc. (RCKT) has a market capitalisation of $ 2,621 Mln as on 29-Feb-2024. As per Value Research classification, it is a Small Cap company.

        The P/B ratio of Rocket Pharmaceuticals Inc. (RCKT) is 5.32 times as on 29-Feb-2024, a 0.79% premium to its peers’ median range of 2.98 times.

        Since, TTM earnings of Rocket Pharmaceuticals Inc. (RCKT) is negative, P/E ratio is not available.

        Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
        Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
        Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
        Step 4. Search for the Rocket Pharmaceuticals Inc. (RCKT) and enter the required number of quantities and click on buy to purchase the shares of Rocket Pharmaceuticals Inc. (RCKT).

        Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a late-stage biotechnology company that focuses on developing gene therapies for rare and devastating diseases. It has three clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells; leukocyte adhesion deficiency-I, a genetic disorder that causes the immune system to malfunction; and pyruvate kinase deficiency, a rare red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia. The company also has a clinical stage in vivo adeno-associated virus program for Danon disease, a multi-organ lysosomal-associated disorder leading to early death due to heart failure; Plakophilin-2 Arrhythmogenic Cardiomyopathy, an inheritable cardiac disorder; and BAG3 Dilated Cardiomyopathy. It has license agreements with Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas, Centro de Investigacion Biomedica En Red, and Fundacion Instituto de investigacion Sanitaria Fundacion Jimenez Diaz; UCL Business PLC; The Regents of the University of California; and REGENXBIO, Inc. Rocket Pharmaceuticals, Inc. was founded in 1999 and is headquartered in Cranbury, New Jersey. Address: 9 Cedarbrook Drive, Cranbury, NJ, United States, 08512

        The CEO & director of Dr. Gaurav D. Shah M.D.. is Rocket Pharmaceuticals Inc. (RCKT), and CFO & Sr. VP is Ms. Kinnari Patel M.B.A., Pharm.D..

        The promoters of Rocket Pharmaceuticals Inc. (RCKT) have pledged 0% of the total equity as on Sep-23.

        Rocket Pharmaceuticals Inc. (RCKT) Ratios
        Return on equity(%)
        -49.38
        Return on capital employed(%)
        --
        Debt-to-equity ratio
        0
        Dividend yield(%)
        0

        No, TTM profit after tax of Rocket Pharmaceuticals Inc. (RCKT) was $-191 Mln.

        Edit peer-selector-edit
        Please wait...
        Please wait...

        Key Facts

        • Market cap market-cap-information $2,620.90 Mln
        • Revenue (TTM)revenue-information $0.00 Mln
        • Earnings (TTM) earning-information $-190.76 Mln
        • Cash date-information $437.17 Mln
        • Total Debt info $25.18 Mln
        • Insider's Holding 3.48%
        • Liquidity liquidity High
        • 52 Week range week-range $14.89 - 32.45
        • Shares outstanding share-outstanding 90,158,896
        • 10 Years Aggregate:

          CFO: $-804.53 Mln

          EBITDA: $-736.13 Mln

          Net Profit: $-1,095.90 Mln

        About The Company

        • IPO Date 18-Feb-2015
        • CEO & Director Dr. Gaurav D. Shah M.D.
        • President & COO Ms. Kinnari Patel M.B.A., Pharm.D.
        • Listing key-listing NASDAQ: RCKT
        • Country United States
        • Headquarters headquarters Cranbury, NJ
        • Website website https://rocketpharma.com
        • Business

          Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a late-stage biotechnology company that focuses on developing gene therapies for rare and devastating diseases. It has three clinical-stage ex vivo lentiviral vector programs...  for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells; leukocyte adhesion deficiency-I, a genetic disorder that causes the immune system to malfunction; and pyruvate kinase deficiency, a rare red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia. The company also has a clinical stage in vivo adeno-associated virus program for Danon disease, a multi-organ lysosomal-associated disorder leading to early death due to heart failure; Plakophilin-2 Arrhythmogenic Cardiomyopathy, an inheritable cardiac disorder; and BAG3 Dilated Cardiomyopathy. It has license agreements with Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas, Centro de Investigacion Biomedica En Red, and Fundacion Instituto de investigacion Sanitaria Fundacion Jimenez Diaz; UCL Business PLC; The Regents of the University of California; and REGENXBIO, Inc. Rocket Pharmaceuticals, Inc. was founded in 1999 and is headquartered in Cranbury, New Jersey. Address: 9 Cedarbrook Drive, Cranbury, NJ, United States, 08512  Read more

        share-fund-plan-icon